Tezepelumab Completed Phase 3 Trials for Moderate to Severe Asthma Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT05062759Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma